Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Current regulations tend to focus on AI developers and purchasers, leaving end-users - the doctors, nurses, and clinicians ...

When it comes to real-world evaluation, appropriate benchmarks need to be carefully selected to match the context of AI ...

Artificial Intelligence (AI) is poised to revolutionize numerous aspects of human life, with health care among the most ...

Adults express a mild preference for messages written by artificial intelligence (AI) versus humans in patient-clin ...

Insilico Medicine('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...

AI is transforming scientific discovery, but AI researchers aren’t at the forefront. What’s stopping them from taking the ...

An AI application takes electronic health records from six in-patient hospitals and more than 300 outpatient locations across ...

In a Duke Health-led survey, patients who were shown messages written either by artificial intelligence (AI) or human ...

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...

Survey respondents preferred patient portal messages written by AI, but their satisfaction decreased when they were told that messages were written by AI.

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...